We are reviewing claims of patients diagnosed with cancer after using Zantac (ranitidine).

Contact us for a case evaluation

Find out quickly and easily if you qualify


Did you take prescription zantac or over-the-counter zantac?

If prescription zantac: Did you take any of following medications:

When did you start taking Zantac?

Did you take zantac for more than 1 year?

Have you been diagnosed with one or more of the following cancers after Zantac usage?

Do have history of smoking?

When was the last time you smoked?

What is the date of your initial cancer diagnosis?

Are you currently represented for this case by another law firm?

Based on your responses, you may qualify for a legal case. Please provide the information below and a representative will contact you shortly.

Best time to reach?

Thousands of Lawsuits Filed in State and Federal Court

Thousands of plaintiffs have filed lawsuits against the manufacturers of Zantac (ranitidine), alleging the medication causes several types of cancer. A California state court judge has scheduled the first trial to begin on October 10, 2022.

Federal lawsuits are pending in federal court in the Southern District of Florida in what is known as multidistrict litigation (MDL). In November 2021, the judge overseeing the MDL outlined procedures for the selection of cases that will proceed as bellwether or test trials, scheduled to begin in the summer of 2023.

Zantac lawsuits have been filed in California, Florida, Illinois (Cook County), New Jersey, New York, Oregon (Portland), Pennsylvania (Philadelphia), and Washington (Seattle) state courts.


June 2019: The online pharmacy and accredited laboratory Valisure notified the US Food and Drug Administration (FDA) that the laboratory had discovered the link between Zantac (ranitidine) and the carcinogen NDMA during routine testing.

September 2019: Valisure filed a detailed Citizen Petition with the U.S. Food and Drug Administration to request a recall of all products containing ranitidine. Testing by Valisure, Stanford University, and others found NDMA was the result of the “inherent instability” of the ranitidine molecule.

Sandoz, Inc., a manufacturer of generic ranitidine, issued a recall. On September 24, the FDA issued a voluntary recall of 14 lots of prescription capsules distributed by Sandoz, Inc. Apotex, another manufacturer of generic ranitidine, issued a recall.

October 2019: Sanofi recalled all over-the-counter Zantac products (Zantac 150, Zantac 150 Cool Mint, Zantac 75) in the US. Various manufacturers of generic ranitidine products issued recalls.

November 2019: A motion was filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate all federally filed lawsuits into one court for pre-trial proceedings. Additional manufacturers issued recalls for their ranitidine products.

January 2020: Emery Pharma filed a Citizens Petition to compel the FDA to suspend sales of all ranitidine products on the market and recall products on the market after the discovery that heat and the lapse of time could raise NDMA levels during storage, shipping, and transport.

February 2020: The JPML orders federal Zantac suits should be centralized in the Southern District of Florida.

April 2020: The FDA requests the removal of all ranitidine (Zantac) products from the market.

November 2021: The judge overseeing the federal MDL issued procedures for selecting bellwether or test trials.

NDMA is classified as a Probable Human Carcinogen

NDMA is classified by the International Agency for Research on Cancer (IARC) as a Class 2A probable human carcinogen based on laboratory test results.